Hypothesis

We hypothesize that the gut microbiome drives rhythmic oscillations in central mTOR activity through timed release of microbial metabolites (e.g., short‑chain fatty acids, indole derivatives) that act as metabolic zeitgebers. When this microbial‑metabolite rhythm is aligned with the host circadian clock, mTOR alternates between anabolic phases that support synaptic plasticity and catabolic phases that promote autophagy, yielding optimal mood and cognition. Chronic disruption of this rhythm—by constant high‑fat diet, antibiotic‑induced dysbiosis, or mistimed prebiotic administration—locks mTOR in either a persistently active or suppressed state, contributing to depressive‑like phenotypes.

Mechanistic Rationale

1. Microbial metabolite release is circadian – Certain SCFA‑producing bacteria exhibit diurnal expression of metabolic enzymes, leading to peaks in circulating acetate, propionate, and butyrate at specific zeitgeber times (1). These metabolites cross the blood‑brain barrier via monocarboxylate transporters and activate GPR41/43, which modulate AMPK and consequently mTORC1 signaling in neurons.
2. mTOR requires oscillatory input for homeostatic signaling – Sustained mTORC1 activation impairs hippocampal long‑term potentiation (3), whereas prolonged inhibition reduces activity‑dependent protein synthesis needed for mood regulation. Oscillatory mTOR activity allows periodic protein synthesis bursts interleaved with autophagic clearance, a pattern observed in circadian regulation of synaptic proteins.
3. Gut‑brain axis provides the timing cue – Germ‑free mice show flattened corticosterone rhythms and blunted mTOR phosphorylation cycles in the prefrontal cortex (2). Colonization with a defined SCFA‑producing consortium restores both microbial metabolite rhythms and neuronal mTOR oscillation amplitude.

Testable Predictions

• Prediction 1: In mice subjected to chronic unpredictable stress, administering a prebiotic blend (e.g., inulin + fructooligosaccharides) at zeitgeber time 4 (early active phase) will restore diurnal SCFA peaks, reinstate hippocampal mTORC1 phosphorylation oscillations, and reverse sucrose‑preference deficits. The same prebiotic given continuously or at zeitgeber time 16 (rest phase) will fail to rescue behavior.
• Prediction 2: Chemogenetic inhibition of intestinal L‑cells (which release peptide YY in response to SCFAs) will abolish the phase‑shifting effect of timed prebiotics on central mTOR rhythms, confirming that gut‑derived hormonal signals mediate the metabolic zeitgeber.
• Prediction 3: Human pilot study: Depressed participants receiving timed probiotic (Lactobacillus rhamnosus GG) capsules at 08:00 h for 4 weeks will show increased evening plasma butyrate, enhanced resting‑state fMRI connectivity between default mode network and prefrontal cortex, and improved MADRS scores relative to those receiving the same probiotic at 20:00 h or a placebo.

Falsifiability

If timed microbial metabolite delivery does not produce measurable changes in central mTOR phosphorylation rhythms (assessed by western blot of phosphorylated S6K in microdissected hippocampal tissue) nor improve mood‑related outcomes, the hypothesis that gut‑microbiota‑driven mTOR oscillation is necessary for affective regulation would be falsified. Conversely, demonstration that constant metabolite supplementation rescues behavior would challenge the requirement for rhythmicity and support a simple dosage model.

Broader Implications

This framework shifts the focus from static mTOR inhibition or activation to restoring dynamic metabolic signaling from the gut. It suggests that chronobiotic interventions—timed prebiotics, probiotics, or microbial metabolite analogs—could be adjuvant to existing antidepressants, targeting the gut‑brain metabolic axis rather than monoaminergic transmission alone.